PMGC Holdings (ELAB) Cash & Current Investments (2022 - 2026)
PMGC Holdings (ELAB) posted Cash & Current Investments of $15.1 million for Q1 2026, up 152.54% sequentially from $6.0 million in Q4 2025, and up 154.78% YoY from $5.9 million in Q1 2025.
PMGC Holdings (ELAB) Cash & Current Investments (2022 - 2026) Analysis & Trends
PMGC Holdings has reported Cash & Current Investments for 5 years, with the latest figure at $15.1 million in Q1 2026.
- Quarterly Cash & Current Investments rose 154.78% year-over-year to $15.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.1 million (up 154.78% YoY) and the FY2025 annual result came in at $6.0 million, up 49.9% from the prior year.
- Cash & Current Investments advanced to $15.1 million in Q1 2026 per ELAB's latest filing, from $6.0 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $1.6 billion in Q3 2022 and troughed at $100034.0 in Q2 2024.
- A 5-year average of $108.9 million and a median of $4.0 million in 2024 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2023 and 2025: Cash & Current Investments slumped 99.97% in 2023, then surged 6205.32% in 2025.
- Over 5 years, Cash & Current Investments stood at $1.2 million in 2022, then jumped by 188.06% to $3.3 million in 2023, then advanced by 19.8% to $4.0 million in 2024, then soared by 49.9% to $6.0 million in 2025, then soared by 152.54% to $15.1 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $15.1 million, $6.0 million, and $8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.14 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 3.31 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.39 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.16 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 836.99 Mn |
| 10 | PMGC Holdings | 31.22 Mn | 12.43 Mn | 385,691.00 | 18.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.09 Mn |
| Dec 31, 2025 | 5.97 Mn |
| Sep 30, 2025 | 8.50 Mn |
| Jun 30, 2025 | 6.31 Mn |
| Mar 31, 2025 | 5.92 Mn |
| Dec 31, 2024 | 3.99 Mn |
| Sep 30, 2024 | 6.43 Mn |
| Jun 30, 2024 | 100,034.00 |
| Mar 31, 2024 | 943,797.00 |
| Dec 31, 2023 | 3.33 Mn |
| Sep 30, 2023 | 476,855.00 |
| Jun 30, 2023 | 601,265.00 |
| Mar 31, 2023 | 1.05 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.57 Bn |